Fulgent Therapeutics

Fulgent Therapeutics was issued its CLIA license (CLIA 05D2043189/CLF 00342581). Apart from traditional single gene tests, Fulgent Therapeutics has been investing heavily in the future. Using Next Generation Sequencing (NGS) technology we are developing a new series of panel based tests for our clients.

Mary Jane Abalos

VP Finance

Ming Hsieh

President and CEO

Paul Kim

CFO

4 past transactions

Spatial Genomics

Series A in 2022
Spatial Genomics is an innovative leaders in the field of spatial analysis, we are dedicated to empowering discovery.We believe that Spatial Genomics will become a standard research tool used routinely by labs worldwide.

CSI Laboratories

Acquisition in 2021
In 2005, CSI Laboratories expanded its product offering by opening its cytogenetics and molecular genetics (FISH) laboratories. To complement these core services, CSI Laboratories built an extensive immunohistochemistry laboratory in 2007. Together with its focus on serving the pathology community and passion for patient-care, CSI Laboratories provides nationwide specialized diagnostic testing aligned with our original mission. CSI Laboratories has provided pathologists and clinicians with the diagnostic expertise they deserve. CSI Laboratories was founded in 1997 as a flow cytometry laboratory with the specific goal of serving the regional community as a dedicated resource for this specialized testing. From the beginning, CSI Laboratories has held client service and patient care in the highest regard.

FF Gene Biotech

Acquisition in 2021
FF Gene Biotech was founded to bring Fulgent Genetics’ Next Generation Sequencing (NGS) capabilities to the Chinese genetic testing market.

Helio Health

Venture Round in 2019
Helio Health is an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw. The company’s mission is to simplify cancer screening so lives can be saved by detecting cancer earlier. With Helio’s AI-driven technology, both physicians and their patients gain powerful insights from accurate, accessible, and convenient blood tests. Helio’s development program is focused on liver, colon, breast and lung cancer. Helio Health is headquartered in Irvine, CA, with R&D, GMP and CLIA facilities in Irvine, CA and West Lafayette, IN.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.